Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.
Engineered T cells kept leukemia from returning in 12 high-risk patients.
The approvals amount to a “game-changer for how we think about treating different groups of patients with AML.”
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
The life-threatening side effect, called differentiation syndrome, is related to the acute myeloid leukemia medicine Idhifa (enasidenib).
A clinical trial showed that 21 percent of participants achieved complete remission.
Daurismo (glasdegib) plus chemotherapy improved overall survival in clinical trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.